Skip to main navigation Skip to search Skip to main content

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

  • Arun A. Azad
  • , Mathias Bressel
  • , Hsiang Tan
  • , Mark Voskoboynik
  • , Aneta Suder
  • , Andrew J. Weickhardt
  • , Alexander Guminski
  • , Roslyn J. Francis
  • , Javad Saghebi
  • , Nattakorn Dhiantravan
  • , Anthony M. Joshua
  • , Louise Emmett
  • , Lisa Horvath
  • , Declan G. Murphy
  • , Edward Hsiao
  • , Bavanthi Balakrishnar
  • , Peter Lin
  • , Andrew Redfern
  • , William Macdonald
  • , Siobhan Ng
    • Sze Ting Lee, David A. Pattison, David Nadebaum, Ian D. Kirkwood, Michael S. Hofman, UpFrontPSMA Study Team, W. Chua, et al.
  • Peter Maccallum Cancer Centre
  • University of Melbourne
  • Royal Adelaide Hospital
  • University of Adelaide
  • Alfred Health
  • Monash University
  • Royal Brisbane and Women's Hospital
  • Austin Health
  • La Trobe University
  • The University of Sydney
  • Sir Charles Gairdner Hospital
  • University of Western Australia
  • Garvan Institute of Medical Research
  • St. Vincent's Hospital Sydney
  • University of New South Wales
  • Chris O'Brien Lifehouse
  • Liverpool Hospital
  • Fiona Stanley Hospital
  • University of Queensland

Research output: Contribution to journal › Article › peer-review

91 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology